Honasa buys 58% of Fluence Pharma for Rs 135 cr, launches Honasa Health to enter VMS market
Mamaearth parent enters Rs 16,000 cr nutraceuticals market at 3.4x FY26 revenue and 15x EBITDA. Dual-channel play: Fluence's dermatologist-led Rx route plus new wholly-owned Honasa Health subsidiary targeting B2C online supplements. Remaining 42% stake to be acquired in 5-7 years.
Honasa Consumer, Mamaearth's parent, acquires 58% of Mumbai-based Fluence Pharma for Rs 135 crore enterprise value, entering nutraceuticals. It also forms wholly-owned subsidiary Honasa Health for B2C online supplements, running parallel to Fluence's dermatologist-led channel.